FY27 Revenue Growth: ~25% YoY
Management guided to approximately 25% topline growth for FY27 based on current order visibility and expansion plans.
MOLBIODIAGNOSTICS / guidance tracker
Keep management guidance in view.
Molbio Diagnostics · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
FY27 EBITDA Margin: 24-25%
Full-year EBITDA margin guidance of 24-25% implies margin stability with potential for improvement as consumable mix increases.
TB Government Contract: 2-Year Visibility
Company renewed its 2-year TB supply contract with Government of India just last month, providing near-term revenue visibility.
HPV Commercialization: Clarity in Q2
Management expects to provide specific volume guidance for HPV government program in the next quarterly call as program details crystallize.
Optra Scan Profitable from FY28
Digital pathology subsidiary (60% owned, fresh $30M capital) received US FDA clearance in July 2025; expected to turn profitable from FY28 onwards.